ReviewJournal of gastrointestinal cancer2014
Primary small-bowel malignancy: update in tumor biology, markers, and management strategies.
Review in Journal of gastrointestinal cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- Intestinal obstruction caused by early stage primary ileum adenocarcinoma: A case report and review of literature.World journal of gastrointestinal oncology · 2025Article
- Simultaneous double primary malignant tumors of MSS/pMMR ascending colon cancer and MSI-H/dMMR duodenal cancer with nearly 2 years of recurrence-free survival after MDT-guided comprehensive treatment: a case report.Frontiers in oncology · 2025Article
- Article
- CT Texture Analysis for Preoperative Identification of Lymphoma from Other Types of Primary Small Bowel Malignancies.BioMed research international · 2021Article
- Misdiagnosis of multiple synchronous small bowel adenocarcinomas as intestinal tuberculosis: a case report.BMC gastroenterology · 2020Article
- Ileal Signet Ring Cell Carcinoma Masked by Crohn Disease.Ochsner journal · 2020Article
- Clinical characteristics of small bowel tumors diagnosed by double-balloon endoscopy: Experience from a Chinese tertiary hospital.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Adenocarcinoma in a Blind Loop of the Ileum 53 Years After an Ileotransversostomy Procedure.The American journal of case reports · 2018Article
- A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis.The World Allergy Organization journal · 2017Article
- Genetic risks and familial associations of small bowel carcinoma.World journal of gastrointestinal oncology · 2016Review
- A potential association between exposure to hepatitis B virus and small bowel adenocarcinoma.Journal of gastrointestinal oncology · 2016Article
- Adenocarcinoma of the ileum: A rare and challenging entity.Annals of medicine and surgery (2012) · 2015Article
- Rare Coexistance of Ileal Diverticulosis, Crohn's Disease and Small Bowel Adenocarcinoma: Report of a Case.In vivo (Athens, Greece)Article
- Most small bowel cancers are revealed by a complication.Einstein (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary small-bowel malignancies (SBM) are rare tumors but their incidence is rising. An estimated 9160 new cases and 1210 deaths due to SBM may occur in the USA in 2014. We review advances made in tumor biology, immunohistochemistry, and discuss treatment strategies for these malignancies.
methodsRelevant articles from PubMed/Medline and Embase searches were collected using the phrases "small-bowel adenocarcinoma, gastrointestinal carcinoids, gastrointestinal stromal tumors, small-bowel leiomyosarcoma, and small-bowel lymphoma".
resultsAdvances in imaging techniques such as wireless capsule endoscopy, CT and MRI enterography, and endoscopy (balloon enteroscopy) along with discovery of molecular markers such as c-kit and PDGFRA for GIST tumors have improved our ability to diagnose, localize, and treat these patients. Early detection and surgical resection offers the best chance for long-term survival in all tumors except bowel lymphoma where chemotherapy plays the main role. Adjuvant therapy with imatinib has improved overall survival for GIST tumors, somatostatin analogs have improved symptoms and also inhibited tumor growth and stabilized metastatic disease in carcinoid disease, but chemotherapy has not improved survival for adenocarcinoma.
conclusionsRecent advances in molecular characterization holds promise in novel targeted therapies. Currently ongoing trials are exploring efficacy of targeted therapies and role of adjuvant therapy for adenocarcinoma and results are awaited. Early detection and aggressive surgical therapy for all localized tumors and lymph node sampling particularly for adenocarcinoma remains the main treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.